MedPath

retrospective study of gamma knife radiosurgery for brain metastases of small cell lung carcinoma after whole brain radiotherapy

Not Applicable
Conditions
brain metastases of small cell lung carcinoma
Registration Number
JPRN-UMIN000027490
Lead Sponsor
Japan Leksell Gamma Knife Society
Brief Summary

The median OS was 9.3 months and the neurologic mortality was 20.0%. Local control failure and new lesion appearance were 36.6% and 64.9%. A BM diameter > 1.0 cm was a significant risk factor for local progression and neurologic death. The symptom improvement was 61.3% and neurological function was preserved for 7.6 months. Therapeutic WBRT was not a significant risk factor for OS, neurological death, local control, or functional deterioration. Symptomatic ARE were 7.4%

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
163
Inclusion Criteria

Not provided

Exclusion Criteria

1 gamma knife radiosurgery before whole brain radiotherapy 2 presence of leptomeningeal dissemination 3 surgery for brain metastases before gamma knife radiosurgery 4 intracranial metastases outside of brain 5 Karnofsky performance status <70 or no expectation for improvement of KPS >60 after gamma knife radiosurgery 6 gamma knife radiosurgery without gadlinium enhancement MRI 7 the number of brain metastases >10 or the total volume of brain metastases >15ml or the volume of maximum brain metastasis >10ml

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath